pimozide has been researched along with Granulocytic Leukemia, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gumus, N; Gunduz, C; Tezcanli Kaymaz, B | 1 |
| Addorio, MR; Bar-Natan, M; Barrett, R; Ebert, BL; Frank, DA; Gashin, LB; Griffin, JD; Klitgaard, JL; Nelson, EA; Santo, L; Terrell, S; Walker, SR; Weisberg, E | 1 |
2 other study(ies) available for pimozide and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
STAT5 inhibitor Pimozide as a probable therapeutic option in overcoming Ponatinib resistance in K562 leukemic cells.
Topics: Apoptosis; Aryldialkylphosphatase; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pimozide; Protein Kinase Inhibitors; Proteins; Pyridazines; STAT5 Transcription Factor | 2023 |
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
Topics: Antineoplastic Agents; Cell Survival; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Molecular Targeted Therapy; Pimozide; Protein Kinase Inhibitors; STAT5 Transcription Factor; Treatment Failure; Tumor Cells, Cultured | 2011 |